Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab or Rilotumumab with Chemotherapy in SCLC
NCT00791154Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2008
- Primary completion
- Feb 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 2, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Ganitumab Arm, Rilotumumab Arm and Placebo Arm (3 arms). Primary endpoints: Overall Survival in Ganitumab Treated Subjects - Phase 2 at 14 months, Overall Survival in Rilotumumab Treated Subjects - Phase 2 at 14 months and 1 more. Started Dec 2008; status: terminated.
02
Drugs
ganitumabrilotumumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00791154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791154.